These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22125315)

  • 1. Transient muscle paralysis degrades bone via rapid osteoclastogenesis.
    Aliprantis AO; Stolina M; Kostenuik PJ; Poliachik SL; Warner SE; Bain SD; Gross TS
    FASEB J; 2012 Mar; 26(3):1110-8. PubMed ID: 22125315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oleanolic acid exerts inhibitory effects on the late stage of osteoclastogenesis and prevents bone loss in osteoprotegerin knockout mice.
    Zhao D; Shu B; Wang C; Zhao Y; Cheng W; Sha N; Li C; Wang Q; Lu S; Wang Y
    J Cell Biochem; 2020 Jan; 121(1):152-164. PubMed ID: 31318102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ionizing Radiation Stimulates Expression of Pro-Osteoclastogenic Genes in Marrow and Skeletal Tissue.
    Alwood JS; Shahnazari M; Chicana B; Schreurs AS; Kumar A; Bartolini A; Shirazi-Fard Y; Globus RK
    J Interferon Cytokine Res; 2015 Jun; 35(6):480-7. PubMed ID: 25734366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RARγ is a negative regulator of osteoclastogenesis.
    Green AC; Poulton IJ; Vrahnas C; Häusler KD; Walkley CR; Wu JY; Martin TJ; Gillespie MT; Chandraratna RA; Quinn JM; Sims NA; Purton LE
    J Steroid Biochem Mol Biol; 2015 Jun; 150():46-53. PubMed ID: 25800721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle paralysis induces bone marrow inflammation and predisposition to formation of giant osteoclasts.
    Ausk BJ; Worton LE; Smigiel KS; Kwon RY; Bain SD; Srinivasan S; Gardiner EM; Gross TS
    Am J Physiol Cell Physiol; 2017 Nov; 313(5):C533-C540. PubMed ID: 28855162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Action of RANKL and OPG for osteoclastogenesis.
    Kobayashi Y; Udagawa N; Takahashi N
    Crit Rev Eukaryot Gene Expr; 2009; 19(1):61-72. PubMed ID: 19191757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
    Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
    Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (2S)-2'-Methoxykurarinone inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling.
    Kim JY; Kim JY; Kim JJ; Oh J; Kim YC; Lee MS
    Biol Pharm Bull; 2014; 37(2):255-61. PubMed ID: 24492722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (-)-Epigallocatechin-3-gallate inhibits RANKL-induced osteoclastogenesis via downregulation of NFATc1 and suppression of HO-1-HMGB1-RAGE pathway.
    Nishioku T; Kubo T; Kamada T; Okamoto K; Tsukuba T; Uto T; Shoyama Y
    Biomed Res; 2020; 41(6):269-277. PubMed ID: 33268671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
    Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
    Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (-)-Epicatechin 3-O-β-D-allopyranoside prevent ovariectomy-induced bone loss in mice by suppressing RANKL-induced NF-κB and NFATc-1 signaling pathways.
    Hsiao HB; Wu JB; Lin WC
    BMC Complement Altern Med; 2017 May; 17(1):245. PubMed ID: 28468652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
    Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
    Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis.
    Cheng J; Liu J; Shi Z; Jules J; Xu D; Luo S; Wei S; Feng X
    J Interferon Cytokine Res; 2012 Jan; 32(1):34-45. PubMed ID: 22142221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor activator of nuclear factor-kappaB ligand-induced nuclear factor of activated T cells (C1) autoregulates its own expression in osteoclasts and mediates the up-regulation of tartrate-resistant acid phosphatase.
    Fretz JA; Shevde NK; Singh S; Darnay BG; Pike JW
    Mol Endocrinol; 2008 Mar; 22(3):737-50. PubMed ID: 18063694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
    Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
    Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation.
    Song C; Tan P; Zhang Z; Wu W; Dong Y; Zhao L; Liu H; Guan H; Li F
    FASEB J; 2018 Jun; 32(6):3215-3228. PubMed ID: 29401617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.
    Jules J; Zhang P; Ashley JW; Wei S; Shi Z; Liu J; Michalek SM; Feng X
    J Biol Chem; 2012 May; 287(19):15728-38. PubMed ID: 22416138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agrimophol suppresses RANKL-mediated osteoclastogenesis through Blimp1-Bcl6 axis and prevents inflammatory bone loss in mice.
    Cao J; Wang S; Wei C; Lin H; Zhang C; Gao Y; Xu Z; Cheng Z; Sun WC; Wang HB
    Int Immunopharmacol; 2021 Jan; 90():107137. PubMed ID: 33199235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.